FDA Approval for Provention Bio (PRVB).

Re-cork the Champagne! We were contemplating (dreaming) about an opening price over $12, and then a drift up towards $20, sometime during 2023. But no,...

Adding Ardelyx (ARDX) $1.57 to Watch List.

FDA Advisory Committee Says Go Forth Young Man! While we hadn't previously owned Ardelyx, nor are they a client - there are a number of...

Provention Biosciences (PRVB) Enters the Danger Zone.

Chart Looks Beautiful - But Nervous is why, we use soft and dry. LIVE QUOTE We'll be short and sweet. We make no prediction as for...

Revive Therapeutics (RVVTF) Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA

TORONTO, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company...

Revive (RVVTF) Hits a Snag?

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 First our summary."FDA provided communication that the amended protocol is still under...

Revive Therapeutics (RVVTF) Annual Shareholder Meeting.

ANNUAL SHAREHOLDER MEETING https://vimeo.com/752050831 CORPORATE PRESENTATION | AUGUST 2022 NEWS ARCHIVE

Adding Progressive Care (RXMD) $0.04 to Watch List.

Adding to Biotech Stock Review 2022 Watch List. Speculative, Yes. But Pay Down of $2 Million Toxic Note and Move into Remote Patient Monitoring Makes...

Provention Bio (PRVB) Announces $125 Million Term Loan Facility with Hercules Capital

Don't think we've ever seen anything like this before. Most investors who prefer to invest post FDA approval, invest post FDA approval. They got...
Dr John Fahy UCSF

Revive Therapeutics (RVVTF) Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company...

Revive Therapeutics (RVVTF) Enters the Danger Zone.

What Danger You Ask? Danger #1, the FDA doesn't like the data, and you own the stock. Danger #2, the FDA does like the data, and...

Latest article

Annette L. Redmond Joins Strategic Advisory Board at Sekur Private Data (SWISF).

Former U.S. State Department Deputy Assistant Secretary Decorated intelligence and cybersecurity executive with four decades of U.S. government leadership joins Sekur to advise on secure...

10X Alerts: Sekur Private Data (SWISF) Pushes SekurOne Closer to Market With First International...

Sekur has completed its first domestic and international encrypted calls on SekurOne and launched the platform’s voice, email, messenger, and VPN capabilities on Android...

Could a Record El Niño Ignite the Next Vaccine Trade?

Chikungunya, Dengue Fever, Rift Valley Fever and Zika The Coming El Niño: An Overlooked Catalyst for Vaccine Stocks? Investors obsess over interest rates, tariffs and AI....